Drug
K-115 clinical trials
Also written Ripasudil, Glanatec and K-321.
Keep track of what changes. Save the K-115 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 8
Kowa Research Institute, Inc. (4) · Stanford University (2) · Kyushu University (1) · Asociación para Evitar la Ceguera en México (1) · Singapore Eye Research Institute (1) · Michael D. Straiko, MD (1) · Marian Macsai, MD (1) · University of Erlangen-Nürnberg Medical School (1)
Studies
Open first, then newest update. How each study uses K-115 is read from its arms, and is right about nine times in ten.
Testing it · 12
- Descemet Endothelial Thickness Comparison Trial IIRecruitingPhase 3Stanford UniversityNCT05275972Written as Ripasudil
- Study to Assess Safety and Tolerability of Multiple Doses of EO2002RecruitingPhase 1Asociación para Evitar la Ceguera en MéxicoNCT05636579Written as Ripasudil
- The Effects of Ripasudil in Patients with FED Undergoing Femtosecond Laser Assisted Cataract SurgeryRecruitingPhase 3Singapore Eye Research InstituteNCT06048380Written as Ripasudil
- Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' DystrophyRecruitingPhase 2Michael D. Straiko, MDNCT03813056Written as Glanatec
- Glanatec(R) for Descemet Stripping in Fuch's Endothelial DystrophyRecruitingPhase 4Marian Macsai, MDNCT03249337Written as Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
- A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract SurgeryCompletedPhase 3Kowa Research Institute, Inc.NCT05528172Written as Ripasudil
- Descemet Endothelial Thickness Comparison Trial IActive, not recruitingPhase 3Stanford UniversityNCT05289661Written as Topical Ripasudil
- A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedPhase 3Kowa Research Institute, Inc.NCT05795699Written as Ripasudil
- A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedPhase 3Kowa Research Institute, Inc.NCT05826353Written as Ripasudil
- Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following DescemetorhexisCompletedPhase 2Kowa Research Institute, Inc.NCT04250207Written as K-321 Solution
- PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of PrematurityCompletedPhase 1/2Kyushu UniversityNCT04621136Written as Ripasudil ophthalmic solution 0.4%
- Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal DystrophyStatus unknownPhase 2University of Erlangen-Nürnberg Medical SchoolNCT03575130Written as Ripasudil eye drops
As the comparator · 1 — what is tested is compared with K-115
Codes
What other systems call K-115 · ClinicalTrials.gg INT006386
- MeSH (NLM) C584679K-115One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584679 | K-115 | One source ClinicalTrials.gov |
Also registered as ripasudil (UNII 11978226XX) and ripasudil hydrochloride (UNII 016TTR32QF).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.